Chemotherapy Induced Nausea and Vomiting – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Chemotherapy Induced Nausea and Vomiting – Pipeline Review, H1 2017’, provides an overview of the Chemotherapy Induced Nausea and Vomiting pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Nausea and Vomiting, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Nausea and Vomiting and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Nausea and Vomiting

The report reviews pipeline therapeutics for Chemotherapy Induced Nausea and Vomiting by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Chemotherapy Induced Nausea and Vomiting therapeutics and enlists all their major and minor projects

The report assesses Chemotherapy Induced Nausea and Vomiting therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Chemotherapy Induced Nausea and Vomiting

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Nausea and Vomiting

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Nausea and Vomiting pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Acacia Pharma Ltd

Aphios Corp

Astellas Pharma Inc

Camurus AB

Daewoong Pharmaceutical Co Ltd

Heron Therapeutics Inc

INSYS Therapeutics Inc

Kyowa Hakko Kirin Co Ltd

MannKind Corp

Medlab Clinical Ltd

Nemus Bioscience Inc

RedHill Biopharma Ltd

Serina Therapeutics Inc

SoluBest Ltd

Suda Ltd

Tesaro Inc

Therapix Biosciences Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Chemotherapy Induced Nausea and Vomiting - Overview

Chemotherapy Induced Nausea and Vomiting - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Chemotherapy Induced Nausea and Vomiting - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Chemotherapy Induced Nausea and Vomiting - Companies Involved in Therapeutics Development

Acacia Pharma Ltd

Aphios Corp

Astellas Pharma Inc

Camurus AB

Daewoong Pharmaceutical Co Ltd

Heron Therapeutics Inc

INSYS Therapeutics Inc

Kyowa Hakko Kirin Co Ltd

MannKind Corp

Medlab Clinical Ltd

Nemus Bioscience Inc

RedHill Biopharma Ltd

Serina Therapeutics Inc

SoluBest Ltd

Suda Ltd

Tesaro Inc

Therapix Biosciences Ltd

Chemotherapy Induced Nausea and Vomiting - Drug Profiles

(netupitant + palonosetron hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(palonosetron hydrochloride + Pro-netupitant) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APD-403 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aprepitant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aprepitant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aprepitant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cannabis CINV - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dronabinol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FK-886 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fosnetupitant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

granisetron hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

granisetron hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

granisetron hydrochloride ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LPI-1504 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LPI-1505 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NB-1222 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NB-2111 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ondansetron hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ondansetron hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ondansetron hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ondansetron hydrochloride CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

palmidrol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

palonosetron hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rolapitant hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SER-232 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Zindol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chemotherapy Induced Nausea and Vomiting - Dormant Projects

Chemotherapy Induced Nausea and Vomiting - Discontinued Products

Chemotherapy Induced Nausea and Vomiting - Product Development Milestones

Featured News & Press Releases

Feb 27, 2017: TESARO Receives Positive CHMP Opinion for VARUBY

Feb 23, 2017: Tesaro Receives CHMP Positive Opinion for Varuby (rolapitant)

Jan 12, 2017: Heron Announces Submission of CINVANTI NDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)

Jan 11, 2017: TESARO Receives Complete Response Letter for Rolapitant IV from U.S. FDA

Oct 27, 2016: Mundipharma Launches Step-change Cancer Care Medicine Akynzeo in Singapore

Sep 06, 2016: TESARO to present data on Rolapitant at the 2016 European Society for Medical Oncology Annual Meeting

Jun 23, 2016: TESARO Announces Rolapitant Data Presentations at the 2016 MASCC/ISOO Annual Meeting on Supportive Care in Cancer

Jun 04, 2016: TESARO Provides Update on Rolapitant IV at ASCO Investor Briefing

May 18, 2016: TESARO Announces Two Abstracts on (VARUBI) Rolapitant to be Presented at the 2016 American Society of Clinical Oncology Annual Meeting

Apr 12, 2016: Suda Granted Canadian Patent For Sud-002 Oral Spray To Treat Nausea & Vomiting

Mar 23, 2016: TESARO Announces Validation of Marketing Authorisation Application for Oral Rolapitant by the European Medicines Agency

Mar 14, 2016: TESARO Submits New Drug Application for Intravenous Rolapitant to the U.S. Food and Drug Administration

Feb 01, 2016: Biologics Announces New Oncology Partnership

Dec 15, 2015: Swissmedic Approves Akynzeo (netupitant/palonosetron) for use in the Prevention of Chemotherapy Induced Nausea and Vomiting in Switzerland

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Chemotherapy Induced Nausea and Vomiting, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Chemotherapy Induced Nausea and Vomiting – Pipeline by Acacia Pharma Ltd, H1 2017

Chemotherapy Induced Nausea and Vomiting – Pipeline by Aphios Corp, H1 2017

Chemotherapy Induced Nausea and Vomiting – Pipeline by Astellas Pharma Inc, H1 2017

Chemotherapy Induced Nausea and Vomiting – Pipeline by Camurus AB, H1 2017

Chemotherapy Induced Nausea and Vomiting – Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017

Chemotherapy Induced Nausea and Vomiting – Pipeline by Heron Therapeutics Inc, H1 2017

Chemotherapy Induced Nausea and Vomiting – Pipeline by INSYS Therapeutics Inc, H1 2017

Chemotherapy Induced Nausea and Vomiting – Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017

Chemotherapy Induced Nausea and Vomiting – Pipeline by MannKind Corp, H1 2017

Chemotherapy Induced Nausea and Vomiting – Pipeline by Medlab Clinical Ltd, H1 2017

Chemotherapy Induced Nausea and Vomiting – Pipeline by Nemus Bioscience Inc, H1 2017

Chemotherapy Induced Nausea and Vomiting – Pipeline by RedHill Biopharma Ltd, H1 2017

Chemotherapy Induced Nausea and Vomiting – Pipeline by Serina Therapeutics Inc, H1 2017

Chemotherapy Induced Nausea and Vomiting – Pipeline by SoluBest Ltd, H1 2017

Chemotherapy Induced Nausea and Vomiting – Pipeline by Suda Ltd, H1 2017

Chemotherapy Induced Nausea and Vomiting – Pipeline by Tesaro Inc, H1 2017

Chemotherapy Induced Nausea and Vomiting – Pipeline by Therapix Biosciences Ltd, H1 2017

Chemotherapy Induced Nausea and Vomiting – Dormant Projects, H1 2017

Chemotherapy Induced Nausea and Vomiting – Dormant Projects, H1 2017 (Contd..1), H1 2017

Chemotherapy Induced Nausea and Vomiting – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Chemotherapy Induced Nausea and Vomiting, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports